Menu

Metabolic Changes Induced by NMN in Healthy Subjects with Acute Binge Drink (NMN-MeABD)

Status and phase

Active, not recruiting
Phase 2

Conditions

Liver Injury
Nutritional Supplementation
Hepatic Steatosis
Binge Drinking

Treatments

Dietary Supplement: β-nicotinamide Mononucleotide
Dietary Supplement: Maltodextrin

Study type

Interventional

Funder types

Other

Identifiers

NCT05882214
Alleviate a hangover with NMN

Details and patient eligibility

About

The goal of this double-blinded, randomized, crossover trial is to investigate the effects of NMN supplementation on liver function, liver fat content and lipid metabolism in healthy young subjects with acute binge drink. The main questions it aims to answer are:

  1. if NMN administration could accelerate alcohol metabolism and alleviate hangover symptom;
  2. if NMN administration could alleviate alcohol-induced liver injury and hepatic steatosis.

Full description

The goal of this double-blinded, randomized, crossover trial is to investigate the effects of NMN supplementation on liver function, liver fat content and lipid metabolism in healthy young subjects with acute binge drink. The main questions it aims to answer are:

  1. if NMN administration could accelerate alcohol metabolism and alleviate hangover symptom;
  2. if NMN administration could alleviate alcohol-induced liver injury and hepatic steatosis.

Participants will be randomized into two groups (n=20), and take 4 NMN capsules (250mg/capsule) or 4 placebo capsules (maltodextrin), respectively. 15 minutes later, they are successively provided with same breakfast and then vodka with a dose of 1g/kg body weight. Venous blood are collected at 0h, 1h, 2h, 3h, 4h, 8h, 12h and 24h from each subject, respectively. In addition, nuclear magnetic resonance imaging (MRI) are taken at 0h, 4h and 24h after alcohol intake. After a 7-day washout period, volunteers are crossed over to another alternative group to receive the corresponding capsules and the test protocol repeats twice.

Enrollment

22 patients

Sex

Male

Ages

18 to 30 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

  1. Inclusion Criteria:

    a. Sign informed consent

  2. Exclusion Criteria:

    1. Neurological disorders
    2. Alcohol allergy
    3. Alcohol addiction
    4. Gastrointestinal diseases
    5. Liver, kidney, cardiovascular or systemic diseases
    6. Antibiotics were administered within 2 weeks prior to the trial
    7. Participants who ate a vegetarian diet
    8. Unable to use a smartphone or computer with Internet access
    9. Participate in another intervention study

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

22 participants in 2 patient groups, including a placebo group

maltodextrin group
Placebo Comparator group
Description:
4 capsule with 1000mg ''maltodextrin''
Treatment:
Dietary Supplement: Maltodextrin
β-nicotinamide mononucleotide group
Experimental group
Description:
4 capsule with 1000mg ''β-nicotinamide mononucleotide''
Treatment:
Dietary Supplement: β-nicotinamide Mononucleotide

Trial contacts and locations

1

There are currently no registered sites for this trial.

Central trial contact

Kaixin Pan

Timeline

Last updated: Jan 20, 2025

Start date

Mar 01, 2024 • 11 months ago

End date

Jan 30, 2025 • 23 days ago

Today

Feb 22, 2025

Sponsor of this trial

Data sourced from clinicaltrials.gov